CPT Codes Are Frequently Flogged for Hurting Innovation. Have Critics Created a Scapegoat? | GenomeWeb

The medical reimbursement landscape in the United States today is too immature for many emerging molecular diagnostics products to gain traction in the marketplace, according to several people familiar with the industry.

Conventional wisdom has it that this archaic, lumbering system may also exert a financial strain on innovators and their reference lab customers because it may discourage payors from reimbursing physicians or patients who use them.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.